DNA Testing

DNA tests to provide actionable lifestyle solutions based on genetics and lifestyle.

  • A U.S. health and wellness company that has innovated, patented and commercialized a proprietary suite of DNA tests andweb-based interpretive software.

  • Technology protected by 28 U.S and International patents (including China), IP fundamental to any approach.

  • DNA tests and online diet and exercise planning products are part of the growing $1.4T global personalized medicine and $850B weight loss product markets.

Founder : Mr. Vince
Location : Los Angeles, CA
Target : $10,000,000
Share Type : Common Stock

Business Overview

    The Company developed and validated scientific and internet products and provides proprietary genetic testing services in compliance with U.S. CMS/CLIA certification (Centers for Medicare and Medicaid/Clinical Laboratory Improvement Amendment, https://www.cms.gov/).. The Company’s core technology is protected by an IP library of 28 U.S and International patents (including in China) and is positioned to become the practical “Genetic Nutrition, Fitness and Weight Management App” for the $1T+ global personalized health market.

Transaction Overview

    The Company’s current line of commercialized DNA tests, CLIA-Certified lab facility, interpretive rules engine software and intellectual property assets were funded with $40M. The Company now seeks $50M to expand distribution of its existing DNA Nutrition Test and DNA Fitness Test products sold through U.S. health care professionals. The Company also will use these funds to expand more aggressively into the obesity market in prevention, management and therapeutics. As the Company generates revenue from its newly developed DNA Weight Management Test in the U.S. health care professional market, it will simultaneously use these new investment resources to enhance the obesity offering to meet the FDA requirements of an In Vitro Diagnostic (IVD). This strategy will allow the Company to:

    1. partner with corporate entities in disease related markets;
    2. participate in the integrated health care market;
    3. become eligible for third-party U.S. insurance payors and reimbursement by U.S. CMS;
    4. support market launch and further CFDA acceptance of our DNA Obesity productsin China; and
    5. implement parallel technology and regulatory strategies in a sister DNA test lab based in China.

Investment Highlight


  • Intellectual Property Estate: the Company's technology is protected by 28 foundational patents in genetic health and wellness, including the U.S., China, Japan, Canada, Australia and Mexico. A key Intellectual Property (IP) asset is the issued U.S. patent covering computational methods of generating wellness recommendations based on genetics and lifestyle information, fundamental to any approach using diet and exercise to guide nutrition and fitness. The Company patents not only protect its existing DNA tests and web-based wellness solutions, but open far-reaching opportunities to protect derivative IP and drive new innovation.

  • Proven Technology Platform: the Company’s existing DNA Tests and online Action Plan products are sold through a network of U.S. health care practitioners to guide nutrition, fitness, weight management, health and wellness interventions unique to individual patients. The Company currently has a database of over 40,000 paid-for genetic and self-reported lifestyle records from testing the ethnically-diverse population of the U.S., with approximately 30-40% representation of Asian ethnicities. The Company’s proprietary DNA test protocols and web-based rules engine software are built to: leverage our IP estate; foster ongoing product improvements and innovations as the science advances; and scale quickly and efficiently to meet growing market demand for genetically-guided personalization products and services.

  • Broad Market Applications: the Company’s DNA Tests and interpretations of individual genetic profiles are captured in easy-to-read Action Plans to guide both health care professionals and patients.These recommendations lead to business partnering opportunities with larger entities, in such markets as personalized: meal planning; vitamin supplementation; exercise regimens; coaching programs for elite athletes; weight loss;corporate wellness; and integrated managed care programs, to increase the outcome and effectiveness of major treatments and medical interventions.

About Management Team

  • Vince, CEO:
    Mass market health/tech product/brand innovation management; MA, Arts & Sciences, Columbia University.

  • Gee, PhD, CSO:
    Science/technology to market leadership; PhD, Simon Fraser University, Canada

  • Kennedy, COO:
    IP product/brand IP content creator, marketing strategist, MBA, USC Marshall School of Business

  • Gillanders, CFO:
    U.K. Chartered Accountant, MBA, University of Florida

About Our Product

    The Company built and commercialized a line of at home cheek-swab genetic tests, including “DNA Nutrition”,“DNA Fitness”and“DNA Weight Management” Assessments and online Action Plans. The existing test is currently sold through U.S. medical doctors and alternative health care professionals. The Company’s DNA Fitness product is currently being targeted to professional sports teams, elite athletes, sports medicine and nutrition professionals, trainers, coaches, gym chains and fitness organizations. The Company also has built a DNA Weight Management Test; formulated a companion suite of proprietary nutrition, fitness and supplement products; and programmed online personalized meal and exercise planning services. Test results are generated by a proprietary, web-based Gene/LifeStyle software that:

    1. combines the genetic and self-reported lifestyle information;
    2. translates the clinical results into a genetic profile for each individual;
    3. provides genetically-guided recommendations for diet and exercise;
    4. can be programmed to specify third-party diet and exercise products; and
    5. can be expanded to high volumes and multiple languages, brands and products.

About Industry

    The Company’s products tap into the current $1.4T global demand for Personalized Medicine technology, a market predicted to grow to $2.45T by 2022. A key objective of the Company is to contribute to the mitigation of the global obesity epidemic and related health conditions. The current global weight loss product market stands at $830B and is slated to grow to $1.44T by 2022. Each market has an estimated CAGR of 11%. (Source: MarketsandMarkets, 2015.)

Financials

Available on further discussion with registered investors.

About Competitor

    The Company’s competition is mostly indirect, including several personal genetics companies delivering primarily genetic data without any actionable recommendations. Others report on disease states (diagnostics), paternity and ancestry testing. Other indirect competitors consist mostly of “algorithms companies” that license or take outside lab developed tests results and provide nutrigenetic interpretation overlay services. Our direct competition comes from a small number of life sciences companies that develop patented genetic “lab developed tests” in wholly owned labs, few of which focus on the Company’s core competencies in nutrigenetic testing and interpretation.The Company is well positioned against both direct and indirect competitors based on its:

    • Patent estate that protects all analyses, internet software, product assets and innovations;
    • Commitment to providing actionable recommendations based on DNA – not just data;
    • Proprietary test product development in a wholly owned government-certified DNA test lab;
    • Internal Scientific and IT R&D on analysis software and web results delivery systems;
    •Strict regulatory compliance stance.

Exit Strategy

Available on further discussion with registered investors.
Risk Warnings
Disclosure: Investing in startups carries a high degree of risk. In general, financial and operating risks confronting both early and developmental-stage companies, as well as more mature expansion-stage companies are significant. Many emerging growth companies go out of businesses every year. It is difficult to know how companies will grow, if at all, or what changes may occur in the market. A loss of an investors entire investment is possible and no profit may be realized. Investors are responsible for conducting their own due diligence. * It should not be assumed that recommendations made in the future will be profitable or will equal the performance of securities in this list
    The Company built and commercialized a line of at home cheek-swab genetic tests, including “DNA Nutrition”,“DNA Fitness”and“DNA Weight Management” Assessments and online Action Plans. The existing test is currently sold through U.S. medical doctors and alternative health care professionals. The Company’s DNA Fitness product is currently being targeted to professional sports teams, elite athletes, sports medicine and nutrition professionals, trainers, coaches, gym chains and fitness organizations. The Company also has built a DNA Weight Management Test; formulated a companion suite of proprietary nutrition, fitness and supplement products; and programmed online personalized meal and exercise planning services. Test results are generated by a proprietary, web-based Gene/LifeStyle software that:

    1. combines the genetic and self-reported lifestyle information;
    2. translates the clinical results into a genetic profile for each individual;
    3. provides genetically-guided recommendations for diet and exercise;
    4. can be programmed to specify third-party diet and exercise products; and
    5. can be expanded to high volumes and multiple languages, brands and products.